-

Agilent Announces Innovative J&W 5Q GC/MS Columns for Superior Gas Chromatograph Performance

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc., (NYSE: A) today announced the release of its new Agilent J&W 5Q GC/MS Columns, representing a major advance in gas chromatography/mass spectrometry (GC/MS) column technology. Agilent has a 50-year history of innovation in gas chromatography, continually setting the standard for GC column performance. The new Agilent J&W 5Q GC/MS columns combine Agilent’s industry-recognized ultra-inert performance and ultra-low-bleed technology, delivering unmatched performance and durability for the most demanding applications.

In modern gas chromatography/mass spectrometry (GC/MS) workflows, GC/MS columns are often subjected to complex matrices and chemically active analytes that require reporting at trace levels. Under these conditions, maintaining the data quality needed to meet regulatory targets or other analytical requirements necessitates more frequent column changes, source cleaning, and potential sample re-runs, which decreases laboratory efficiency and increases costs.

Agilent J&W GC/MS 5Q columns provide exceptional peak symmetry for active analytes and set a new industry standard for minimal column bleed, enabling high sensitivity, maintaining accuracy and mass spectral fidelity, and accurate quantitation for the most challenging trace-level analytes. Additionally, these new GC/MS columns feature faster conditioning and are especially resistant to conditions that can shorten column life. Agilent J&W GC/MS 5Q columns enhance system performance in particularly difficult conditions, such as the use of hydrogen as a carrier gas, and in environmental workflows targeting emerging analytes of interest, where exceptional sensitivity and column durability are critical.

“This launch marks one of our most significant advancements in GC/MS column technology. The new J&W 5Q GC/MS columns are engineered to meet the rigorous demands of modern analytical laboratories,” said David Edwards, vice president and general manager of Agilent’s Chemistries Division. “By reducing the frequency of column changes and enhancing system performance, these columns not only improve data quality but also significantly boost laboratory efficiency and reduce operational costs.”

“Eagerly anticipated by our customers, this GC/MS column innovation underscores Agilent’s commitment to providing cutting-edge solutions that empower scientists to achieve their analytical goals with greater ease and reliability,” Edwards added.

Available in a range of dimensions, the Agilent J&W 5Q GC/MS columns extend the analytical options available to labs across a wide sector of markets and applications, including PFAS testing in environmental samples, analysis of residual pesticides in food, and more. Their enhanced performance strengthens Agilent’s position as a premium provider of solutions that push the boundaries of analytical methodology, allowing users of industry-leading Agilent GC/MS systems to extract even greater performance and value from their instruments.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical laboratory technologies, delivering insights and innovation that help our customers bring great science to life. Agilent’s full range of solutions includes instruments, software, services, and expertise that provide trusted answers to our customers' most challenging questions. The company generated revenue of $6.83 billion in fiscal 2023 and employs approximately 18,000 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn and Facebook.

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

AGILENT TECHNOLOGIES INC

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Versions

Contacts

MEDIA CONTACT
Naomi Goumillout
Agilent Technologies
+1.978.314.1862
naomi.goumillout@agilent.com

More News From AGILENT TECHNOLOGIES INC

Agilent Receives European IVDR Certification for Companion Diagnostic Assay in Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR certification for the use as a Companion Diagnostic (CDx) to aid in the identification of gastric or gastroesophageal Junction (GEJ) adenocarcinoma patients who may be eligible for treatment with KEYTRUDA® (pembrolizumab)1. PD-L1 IHC 22C3 pharmDx (Code SK006) is approved for exclusive use with the Agilent Autostainer Link 48 advanced...

Agilent to Announce Second-Quarter Fiscal Year 2025 Financial Results on May 28

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) will release financial results for the second quarter of fiscal year 2025 after the stock market closes on Wednesday, May 28. In addition, the company will host a conference call to discuss the results at 1:30 p.m. PDT on the same day. To join the listen-only conference call webcast, click the link on the Events section of Agilent’s investor relations website. A recording of the call also will be available on the website...

Agilent xCELLigence RTCA Instrumentation Applied in Recent FDA Approval

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics’ FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTCA technology supported the development and implementation of the potency assay. By providing precise a...
Back to Newsroom